Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers. The news flow around OLMA reflects its active clinical development program, capital markets activity, and ongoing corporate updates.
Investors and followers of Olema’s news can expect frequent updates on its lead product candidate, palazestrant (OP-1250), an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being evaluated in ER+/HER2- metastatic breast cancer. Company announcements include progress in pivotal Phase 3 trials such as OPERA-01 and OPERA-02, data presentations from Phase 1b/2 studies of palazestrant in combination with ribociclib, and details on additional Phase 1/2 combination studies with agents like palbociclib, alpelisib, everolimus, and atirmociclib.
Olema’s news stream also covers pipeline developments for OP-3136, a KAT6 inhibitor in Phase 1 clinical evaluation as monotherapy and in combination with fulvestrant and palazestrant in advanced solid tumors. Regulatory and collaboration milestones, such as clinical trial agreements with Pfizer to study palazestrant plus atirmociclib, are disclosed through press releases and SEC filings.
In addition, Olema regularly reports financial and operating results, underwritten public offerings of common stock under its shelf registration on Form S-3, and inducement grants of stock options to new employees under its 2022 Inducement Plan. The company also announces participation in healthcare and investor conferences, where it presents updates on its clinical programs and strategy. Readers who follow OLMA news gain insight into trial progress, collaboration agreements, financing activities, and other corporate events that shape Olema’s development as a clinical-stage oncology company.
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Sean P. Bohen, M.D., President and Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, California.
The presentation will be accessible via live webcast, along with any accompanying materials, through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be made available at the same location following the presentation.
Olema Oncology announced updated clinical results for palazestrant combined with ribociclib in treating ER+/HER2- advanced or metastatic breast cancer. With a 12-month median follow-up, the study showed promising results with median progression-free survival (PFS) not yet reached. The 6-month PFS rate was 73% overall, with 81% in ESR1 mutation patients and 70% in ESR1 wild-type patients.
The Phase 1b/2 study included 62 patients, with 56 receiving the recommended Phase 2 dose. The combination demonstrated favorable tolerability and safety profile consistent with ribociclib and endocrine therapy. Notable outcomes include a 76% clinical benefit rate across all patients and 27% objective response rate in patients with measurable disease.
Olema Pharmaceuticals (Nasdaq: OLMA) announced FDA clearance of its Investigational New Drug (IND) application for OP-3136, a novel small molecule that inhibits KAT6, an epigenetic target involved in breast and other cancers. The company plans to initiate a Phase 1 clinical trial in early 2025. OP-3136 has shown promising preclinical activity both as a standalone treatment and in combination with palazestrant. The drug development represents Olema's continued focus on targeted therapies for breast cancer and other oncology indications.
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to two new employees. The grants, approved by the Compensation Committee, total 60,000 shares under the company's 2022 Inducement Plan.
The options have a 10-year term with an exercise price of $10.21 per share, matching Nasdaq's reported sale price on December 2, 2024. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years, contingent on continued employment.
Olema Oncology has announced two major developments: a clinical trial collaboration with Novartis and a $250 million private placement. The Novartis agreement will provide ribociclib drug supply for the planned Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer, expected to start mid-2025. The private placement involves issuing shares at $9.08 and pre-funded warrants, with participation from notable investors including Adage Capital Partners, Bain Capital Life Sciences, and others. The funding will support OPERA-02, the ongoing Phase 3 OPERA-01 trial (with top-line data expected in 2026), and Phase 1/2 study of OP-3136.
Olema Oncology (Nasdaq: OLMA) announced it will present new data from its Phase 1b/2 clinical study at the San Antonio Breast Cancer Symposium (SABCS 2024). The study focuses on palazestrant (OP-1250) combined with CDK4/6 inhibitor ribociclib for treating ER+/HER2- advanced or metastatic breast cancer.
The poster presentation (ID: P2-09-16) is scheduled for December 11, 2024, from 5:30 to 7:00 p.m. CT in Halls 2-3. Olema will host an investor conference call on December 10, 2024, at 8:00 a.m. ET to discuss the findings. The poster will be available on Olema's website following the symposium's embargo policy.
Olema Oncology (OLMA) reported Q3 2024 financial results with a cash position of $214.8 million as of September 30, 2024. The company recorded a net loss of $34.6 million, up from $21.5 million in Q3 2023, primarily due to increased R&D expenses of $33.2 million. The company presented new preclinical data for OP-3136, their KAT6 inhibitor, and continues enrollment in the OPERA-01 Phase 3 trial of palazestrant. Olema plans to submit an IND application for OP-3136 before year-end and initiate Phase 1 trials in early 2025.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has announced its participation in three upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference on November 20, 2024, at 1:30 p.m. GMT, the Evercore HealthCONx Conference on December 3, 2024, at 2:10 p.m. ET, and Citi's Global Healthcare Conference on December 3, 2024, at 3:15 p.m. ET. The events will feature various presentation formats including fireside chats and panel discussions. Live webcasts will be available on Olema's investor relations website and archived for at least 30 days.
Olema Pharmaceuticals (Nasdaq: OLMA) has granted stock options to one new employee as part of its inducement program. The grant includes options to purchase 2,500 shares of common stock at an exercise price of $11.62 per share. The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology presented preclinical data at ENA 2024 showcasing anti-tumor activity of their drug candidates. OP-3136, a KAT6 inhibitor, demonstrated strong anti-tumor activity alone and enhanced effects when combined with palazestrant. The company plans to submit an IND application for OP-3136 by year-end. Additionally, palazestrant showed improved tumor suppression when combined with everolimus and capivasertib in ER+/HER2- breast cancer models. The studies revealed synergistic effects and significant tumor regression, particularly when palazestrant was combined with these agents, showing superior results compared to fulvestrant combinations.